250.49

2.82% 6.88

West Pharmaceutical Services Inc (WST)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt WST? Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$243.61

Offen:

$243.94

24-Stunden-Volumen:

978.09K

Relative Volume:

1.14

Marktkapitalisierung:

$18.02B

Einnahmen:

$2.96B

Nettoeinkommen (Verlust:

$487.70M

KGV:

37.52

EPS:

6.6758

Netto-Cashflow:

$344.00M

1W Leistung:

+0.62%

1M Leistung:

-7.85%

6M Leistung:

+1.73%

1J Leistung:

+25.80%

1-Tages-Spanne:

$242.14

$250.53

1-Wochen-Bereich:

$227.49

$259.90

52-Wochen-Spanne:

$187.43

$322.34

West Pharmaceutical Services Inc Stock (WST) Company Profile

Firmenname

West Pharmaceutical Services Inc

Sektor

Healthcare (1111)

Branche

Medical Instruments & Supplies (58)

Telefon

(610) 594-2900

Adresse

530 HERMAN O. WEST DRIVE, EXTON, PA

Mitarbeiter

10,600

Twitter

@WestPharma

Nächster Verdiensttermin

2024-10-24

Neueste SEC-Einreichungen

WST's Discussions on Twitter

Compare WST vs ISRG, BDX, ALC, MDLN, RMD

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
WST West Pharmaceutical Services Inc	250.49	17.53B	2.96B	487.70M	344.00M	6.6758
ISRG Intuitive Surgical Inc	485.84	169.97B	10.06B	2.88B	2.49B	7.876
BDX Becton Dickinson Co	175.89	50.58B	21.92B	1.76B	2.63B	6.1223
ALC Alcon Inc	79.20	38.58B	10.19B	1.05B	1.38B	2.1044
MDLN Medline Inc	44.55	37.11B	27.43B	1.27B	1.01B	1.5829
RMD Resmed Inc	252.55	35.80B	5.40B	1.49B	1.78B	10.12

West Pharmaceutical Services Inc Stock (WST) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-02	Eingeleitet	Morgan Stanley	Equal-Weight
2025-09-15	Eingeleitet	Rothschild & Co Redburn	Buy
2025-06-24	Eingeleitet	Barclays	Equal Weight
2025-03-18	Eingeleitet	Evercore ISI	Outperform
2025-02-14	Hochstufung	Deutsche Bank	Hold → Buy
2025-01-08	Eingeleitet	Citigroup	Buy
2024-12-13	Eingeleitet	Wolfe Research	Peer Perform
2024-12-12	Hochstufung	UBS	Neutral → Buy
2024-02-07	Hochstufung	Jefferies	Hold → Buy
2023-06-16	Hochstufung	BofA Securities	Neutral → Buy
2023-04-11	Hochstufung	Stephens	Equal-Weight → Overweight
2022-12-14	Eingeleitet	Deutsche Bank	Hold
2022-11-30	Eingeleitet	UBS	Neutral
2022-10-28	Herabstufung	BofA Securities	Buy → Neutral
2020-11-10	Eingeleitet	KeyBanc Capital Markets	Overweight
2020-10-14	Eingeleitet	Stephens	Equal-Weight
2020-07-21	Hochstufung	BofA Securities	Neutral → Buy
2020-04-24	Hochstufung	BofA/Merrill	Underperform → Neutral
2019-12-12	Herabstufung	BofA/Merrill	Neutral → Underperform
2019-07-26	Hochstufung	BofA/Merrill	Underperform → Neutral
2019-05-01	Herabstufung	Jefferies	Buy → Hold
2019-04-23	Eingeleitet	William Blair	Outperform
2018-04-25	Herabstufung	BofA/Merrill	Neutral → Underperform
2018-01-24	Eingeleitet	Goldman	Neutral
2017-10-17	Herabstufung	BofA/Merrill	Buy → Neutral
2017-10-03	Eingeleitet	Stephens	Equal-Weight
2017-09-15	Hochstufung	Jefferies	Hold → Buy
2016-10-28	Hochstufung	Wells Fargo	Market Perform → Outperform
2016-09-21	Herabstufung	Wells Fargo	Outperform → Market Perform
2016-03-22	Eingeleitet	Wells Fargo	Outperform
2010-05-14	Bestätigt	UBS	Neutral
2010-02-23	Eingeleitet	Jefferies & Co	Buy
2008-12-19	Eingeleitet	UBS	Neutral

Alle ansehen

West Pharmaceutical Services Inc Aktie (WST) Neueste Nachrichten

Feb 13, 2026

West Pharmaceutical Services (WST): Barclays Lowers Price Target - GuruFocus

Feb 13, 2026

Stephens Cuts Price Target on West Pharmaceutical Services to $320 From $350, Maintains Overweight Rating - marketscreener.com

Feb 13, 2026

West Pharmaceutical Services, Inc. (NYSE:WST) Q4 2025 Earnings Call Transcript - Insider Monkey

Feb 13, 2026

West Pharmaceutical Services Q4 Earnings Call Highlights - Yahoo Finance

Feb 13, 2026

West Pharmaceutical targets 5%–7% organic revenue growth for 2026 as HVP demand accelerates - MSN

Feb 13, 2026

Feb 12, 2026

West Pharma forecasts 2026 profit above estimates on strong demand for drug components - 104.1 WIKY

Feb 12, 2026

Earnings call transcript: West Pharmaceutical Services Q4 2025 earnings beat expectations - Investing.com Canada

Feb 12, 2026

West Pharmaceutical Services (WST) Is Up 5.2% After Strong 2025 Results And 2026 Organic Growth Outlook - Yahoo Finance

Feb 12, 2026

West Pharmaceutical Q4 2025 slides: Revenue up 7.5%, EPS exceeds expectations - Investing.com Nigeria

Feb 12, 2026

West Pharmaceutical Services (NYSE:WST) Issues Quarterly Earnings Results, Beats Expectations By $0.21 EPS - MarketBeat

Feb 12, 2026

West Pharmaceutical Services's (NYSE:WST) Q4 CY2025: Beats On Revenue, Stock Soars - Finviz

Feb 12, 2026

WST's Q4 Earnings & Sales Beat, SmartDose Sale by Mid-2026, Stock Up - Finviz

Feb 12, 2026

Iron Mountain Projects Double-Digit Growth in 2026 - Investing.com

Feb 12, 2026

West Pharmaceutical Q4 2025 slides: Revenue up 7.5%, EPS exceeds expectations By Investing.com - Investing.com India

Feb 12, 2026

West Pharmaceutical (WST) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo! Finance Canada

Feb 12, 2026

West Pharmaceutical Services (NYSE:WST) Issues FY 2026 Earnings Guidance - MarketBeat

Feb 12, 2026

In the latest conference call, West Pharmaceutical Services Inc executives noted that although demand for GLP-1 drugs is showing strong growth momentum in 2025, the growth pace is expected to slow down in 2026. - Bitget

Feb 12, 2026

West Pharmaceutical (WST) Exceeds Market Expectations with Stron - GuruFocus

Feb 12, 2026